IntegraGen SA (ALINT.PA)
EUR 0.53
(0.0%)
EUR 0.53
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12.53 Million EUR | -4.78% |
| 2022 | 13.16 Million EUR | 16.27% |
| 2021 | 11.32 Million EUR | 26.11% |
| 2020 | 8.97 Million EUR | 8.45% |
| 2019 | 8.27 Million EUR | 19.12% |
| 2018 | 6.95 Million EUR | 6.8% |
| 2017 | 6.5 Million EUR | 3.77% |
| 2016 | 6.27 Million EUR | 8.37% |
| 2015 | 5.78 Million EUR | -5.57% |
| 2014 | 6.12 Million EUR | 13.24% |
| 2013 | 5.41 Million EUR | 14.17% |
| 2012 | 4.74 Million EUR | 1.97% |
| 2011 | 4.64 Million EUR | 40.47% |
| 2010 | 3.3 Million EUR | 17.66% |
| 2009 | 2.81 Million EUR | 24.48% |
| 2008 | 2.25 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.57 Million EUR | 0.0% |
| 2023 Q2 | 6.08 Million EUR | 0.0% |
| 2023 FY | 12.53 Million EUR | -4.78% |
| 2023 Q4 | 6.48 Million EUR | 0.0% |
| 2022 Q4 | 6.4 Million EUR | 0.0% |
| 2022 FY | 13.16 Million EUR | 16.27% |
| 2022 Q2 | 6.76 Million EUR | 0.0% |
| 2021 Q2 | 5.01 Million EUR | 0.0% |
| 2021 FY | 11.32 Million EUR | 26.11% |
| 2021 Q4 | 6.29 Million EUR | 0.0% |
| 2020 Q2 | 4.7 Million EUR | 0.0% |
| 2020 FY | 8.97 Million EUR | 8.45% |
| 2020 Q4 | 4.27 Million EUR | 0.0% |
| 2019 Q2 | 4.16 Million EUR | 0.0% |
| 2019 FY | 8.27 Million EUR | 19.12% |
| 2019 Q4 | 4.11 Million EUR | 0.0% |
| 2018 Q2 | 3.62 Million EUR | 0.0% |
| 2018 Q4 | 3.32 Million EUR | 0.0% |
| 2018 FY | 6.95 Million EUR | 6.8% |
| 2017 Q2 | 3.22 Million EUR | 0.0% |
| 2017 FY | 6.5 Million EUR | 3.77% |
| 2017 Q4 | 3.28 Million EUR | 0.0% |
| 2016 Q4 | 3.28 Million EUR | 0.0% |
| 2016 Q2 | 2.98 Million EUR | 0.0% |
| 2016 FY | 6.27 Million EUR | 8.37% |
| 2015 FY | 5.78 Million EUR | -5.57% |
| 2015 Q4 | 3.16 Million EUR | 0.0% |
| 2015 Q2 | 2.62 Million EUR | 0.0% |
| 2014 Q4 | 3.51 Million EUR | 0.0% |
| 2014 FY | 6.12 Million EUR | 13.24% |
| 2014 Q2 | 2.61 Million EUR | 0.0% |
| 2013 Q2 | 2.66 Million EUR | 0.0% |
| 2013 Q4 | 2.74 Million EUR | 0.0% |
| 2013 FY | 5.41 Million EUR | 14.17% |
| 2012 Q4 | 1.35 Million EUR | 14.06% |
| 2012 Q3 | 1.18 Million EUR | 0.0% |
| 2012 FY | 4.74 Million EUR | 1.97% |
| 2012 Q1 | 1.18 Million EUR | 0.0% |
| 2012 Q2 | 1.18 Million EUR | 0.0% |
| 2011 Q3 | 1.16 Million EUR | 0.0% |
| 2011 Q1 | 1.16 Million EUR | 0.0% |
| 2011 Q2 | 1.16 Million EUR | 0.0% |
| 2011 Q4 | 1.18 Million EUR | 1.97% |
| 2011 FY | 4.64 Million EUR | 40.47% |
| 2010 Q4 | 1.16 Million EUR | 40.47% |
| 2010 Q3 | 827.47 Thousand EUR | 0.0% |
| 2010 Q1 | 827.47 Thousand EUR | 0.0% |
| 2010 Q2 | 827.47 Thousand EUR | 0.0% |
| 2010 FY | 3.3 Million EUR | 17.66% |
| 2009 FY | 2.81 Million EUR | 24.48% |
| 2009 Q1 | 703.27 Thousand EUR | 0.0% |
| 2009 Q2 | 703.27 Thousand EUR | 0.0% |
| 2009 Q3 | 703.27 Thousand EUR | 0.0% |
| 2009 Q4 | 827.47 Thousand EUR | 17.66% |
| 2008 Q1 | 564.96 Thousand EUR | 0.0% |
| 2008 Q2 | 564.96 Thousand EUR | 0.0% |
| 2008 Q3 | 564.96 Thousand EUR | 0.0% |
| 2008 FY | 2.25 Million EUR | 0.0% |
| 2008 Q4 | 703.27 Thousand EUR | 24.48% |
| 2007 Q4 | 564.96 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -170.203% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -171.314% |
| Adocia SA | 2.15 Million EUR | -483.136% |
| Aelis Farma SA | 9.05 Million EUR | -38.474% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -297.887% |
| genOway Société anonyme | 20.04 Million EUR | 37.458% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -4078.671% |
| Neovacs S.A. | 533.41 Thousand EUR | -2250.422% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -645.603% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -63233.163% |
| Sensorion SA | 4.74 Million EUR | -164.332% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -4130.888% |
| TME Pharma N.V. | 17 Thousand EUR | -73649.606% |
| Valbiotis SA | 4.73 Million EUR | -164.894% |
| TheraVet SA | 1.07 Million EUR | -1062.968% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -596.524% |
| argenx SE | 1.13 Billion EUR | 98.895% |
| BioSenic S.A. | 543 Thousand EUR | -2208.92% |
| Celyad Oncology SA | 102 Thousand EUR | -12191.601% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 94.77% |
| Genfit S.A. | 28.56 Million EUR | 56.109% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -500.739% |
| Innate Pharma S.A. | 51.9 Million EUR | 75.844% |
| Inventiva S.A. | 17.47 Million EUR | 28.263% |
| MaaT Pharma SA | 2.22 Million EUR | -462.721% |
| MedinCell S.A. | 9.16 Million EUR | -36.872% |
| Nanobiotix S.A. | 30.05 Million EUR | 58.289% |
| Onward Medical N.V. | 532 Thousand EUR | -2256.66% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 11.656% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -462.974% |
| Oxurion NV | 263 Thousand EUR | -4667.085% |
| Pharming Group N.V. | 245.31 Million EUR | 94.889% |
| Poxel S.A. | 1.98 Million EUR | -532.884% |
| GenSight Biologics S.A. | 1.26 Million EUR | -889.537% |
| Transgene SA | 1.18 Million EUR | -958.905% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.761% |
| Valneva SE | 153.71 Million EUR | 91.844% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 446.338% |